Immune blood biomarkers of Alzheimer disease patients

Journal of Neuroimmunology

Volumn 210, Issue 1-2, 2009, Pages 67-72

  Avagyan, Hripsime ^a   Goldenson, Ben ^a   Tse, Eric ^a   Masoumi, Ava ^a   Porter, Verna ^b,f   Wiedau Pazos, Martina ^b,f   Sayre, James ^c   Ong, Reno ^a   Mahanian, Michelle ^a   Koo, Patrick ^a   Bae, Susan ^a   Micic, Miodrag ^d   Liu, Philip T ^b   Rosenthal, Mark J ^e   Fiala, Milan ^a  

^a JOINT REPLACEMENT INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MP Biomedicals LLC   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer disease; Amyloid beta; Biomarkers; Macrophages; MGAT III; Phagocytosis

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; TOLL LIKE RECEPTOR 3;

ADULT; AGED; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BLOOD ANALYSIS; CAREGIVER; CEREBROSPINAL FLUID; COGNITION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENETIC TRANSCRIPTION; HUMAN; INNATE IMMUNITY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; PHAGOCYTOSIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION REGULATION; UPREGULATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; BRAIN; EARLY DIAGNOSIS; ENCEPHALITIS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; N-ACETYLGLUCOSAMINYLTRANSFERASES; PHAGOCYTOSIS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOLL-LIKE RECEPTOR 3;

EID: 67349091252     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.02.015     Document Type: Article

References (31)

1. Aggarwal B.B., and Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 71 (2006) 1397-1421
2. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., and Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 21 (2000) 383-421
3. Bhattacharyya R., Bhaumik M., Raju T.S., and Stanley P. Truncated, inactive N-acetylglucosaminyltransferase III (GlcNAc-TIII) induces neurological and other traits absent in mice that lack GlcNAc-TIII. J. Biol. Chem. 277 (2002) 26300-26309
4. Blennow K., and Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2 (2003) 605-613
5. Brooks B.R., Miller R.G., Swash M., and Munsat T.L. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 1 (2000) 293-299
6. Cicuttini F.M., Byron K.A., Maher D., Wootton A.M., Muirden K.D., and Hamilton J.A. Serum IL-4, IL-10 and IL-6 levels in inflammatory arthritis. Rheumatol. Int. 14 (1995) 201-206
7. de Ruijter W., Westendorp R.G., Assendelft W.J., den Elzen W.P., de Craen A.J., le Cessie S., and Gussekloo J. Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ 338 (2009) a3083
8. Fagan A.M., Csernansky C.A., Morris J.C., and Holtzman D.M. The search for antecedent biomarkers of Alzheimer's disease. J. Alzheimer's Dis. 8 (2005) 347-358
9. Fiala M., Cribbs D.H., Rosenthal M., and Bernard G. Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer's disease. J. Alzheimer's Dis. 11 (2007) 457-463
10. Fiala M., Liu P.T., Espinosa-Jeffrey A., Rosenthal M.J., Bernard G., Ringman J.M., Sayre J., Zhang L., Zaghi J., Dejbakhsh S., Chiang B., Hui J., Mahanian M., Baghaee A., Hong P., and Cashman J. Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 12849-12854
11. Guerreiro R.J., Santana I., Bras J.M., Santiago B., Paiva A., and Oliveira C. Peripheral inflammatory cytokines as biomarkers in Alzheimer's disease and mild cognitive impairment. Neurodegener. Dis. 4 (2007) 406-412
12. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
13. Hsieh C.H., Frink M., Hsieh Y.C., Kan W.H., Hsu J.T., Schwacha M.G., Choudhry M.A., and Chaudry I.H. The role of MIP-1alpha in the development of systemic inflammatory response and organ injury following trauma hemorrhage. J. Immunol. 181 (2008) 2806-2812
14. Kahn C.R. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 43 (1994) 1066-1084
15. Laske C., Stransky E., Leyhe T., Eschweiler G.W., Schott K., Langer H., and Gawaz M. Decreased brain-derived neurotrophic factor (BDNF)- and beta-thromboglobulin (beta-TG)- blood levels in Alzheimer's disease. Thromb. Haemost. 96 (2006) 102-103
16. Laske C., Stellos K., Eschweiler G.W., Leyhe T., and Gawaz M. Decreased CXCL12 (SDF-1) plasma levels in early Alzheimer's disease: a contribution to a deficient hematopoietic brain support?. J. Alzheimer's Dis. 15 (2008) 83-95
17. Laske C., Stellos K., Stransky E., Seizer P., Akcay Ö., Eschweiler G.W., Leyhe T., and Gawaz M. Decreased plasma and cerebrospinal fluid levels of stem cell factor in patients with early Alzheimer's disease. J. Alzheimer's Dis. 15 (2008) 451-460
18. Mallone R., and van Endert P. T cells in the pathogenesis of type 1 diabetes. Curr. Diab. Rep. 8 (2008) 101-106
19. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
20. Monsonego A., Zota V., Karni A., Krieger J.I., Bar-Or A., Bitan G., Budson A.E., Sperling R., Selkoe D.J., and Weiner H.L. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J. Clin. Invest. 112 (2003) 415-422
21. Oda K., and Yamamoto Y. Serum interferon-gamma, interleukin-4, and interleukin-6 in infants with adenovirus and respiratory syncytial virus infection. Pediatr. Int. 50 (2008) 92-94
22. Petersen R.C., Doody R., Kurz A., Mohs R.C., Morris J.C., Rabins P.V., Ritchie K., Rossor M., Thal L., and Winblad B. Current concepts in mild cognitive impairment. Arch. Neurol. 58 (2001) 1985-1992
23. Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., Friedman L.F., Galasko D.R., Jutel M., Karydas A., Kaye J.A., Leszek J., Miller B.L., Minthon L., Quinn J.F., Rabinovici G.D., Robinson W.H., Sabbagh M.N., So Y.T., Sparks D.L., Tabaton M., Tinklenberg J., Yesavage J.A., Tibshirani R., and Wyss-Coray T. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 13 (2007) 1359-1362
24. Roychaudhuri R., Yang M., Hoshi M.M., and Teplow D.B. Amyloid {beta}-protein assembly and Alzheimer disease. J. Biol. Chem. 284 (2009) 4749-4753
25. Ruggeri R.M., Barresi G., Sciacchitano S., Trimarchi F., Benvenga S., and Trovato M. Immunoexpression of the CD30 ligand/CD30 and IL-6/IL-6R signals in thyroid autoimmune diseases. Histol. Histopathol. 21 (2006) 249-256
26. Shigeta M., Shibukawa Y., Ihara H., Miyoshi E., Taniguchi N., and Gu J. Beta1,4-N-acetylglucosaminyltransferase III potentiates beta1 integrin-mediated neuritogenesis induced by serum deprivation in neuro2a cells. Glycobiology 16 (2006) 564-571
27. Silverman J.M., Raiford K., Edland S., Fillenbaum G., Morris J.C., Clark C.M., Kukull W., and Heyman A. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part VI. Family history assessment: a multicenter study of first-degree relatives of Alzheimer's disease probands and nondemented spouse controls. Neurology 44 (1994) 1253-1259
28. Tahara K., Kim H.D., Jin J.J., Maxwell J.A., Li L., and Fukuchi K. Role of toll-like receptor signalling in Abeta uptake and clearance. Brain 129 (2006) 3006-3019
29. van Oijen M., Hofman A., Soares H.D., Koudstaal P.J., and Breteler M.M. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 5 (2006) 655-660
30. Zaghi, Goldenson, Inayathullah, Lossinsky A.S., Masoumi A., Avagyan H., Mahanian M., Bernas M., Rosenthal M.J., Espinosa-Jeffrey A., Velllis J.S.D., Teplow D.B., and Fiala M. Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy. Acta. Neuropathol. (2009)
31. Zhang L., Fiala M., Cashman J., Sayre J., Espinosa-Jeffrey A., Mahanian M., Zaghi J., V, B., Graves M., Bernard G., and Rosenthal M. Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer's disease patients. J. Alzheimer's Dis. 10 (2006) 1-7